Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Anal Cancer - Pipeline Review, H1 2019 - ResearchAndMarkets.com

April 16, 2019

DUBLIN--(BUSINESS WIRE)--Apr 16, 2019--The “Anal Cancer - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Anal Cancer - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 16, 10 and 5 respectively.

Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anal Cancer (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered

1. Introduction

2. Anal Cancer - Overview

3. Anal Cancer - Therapeutics Development

4. Anal Cancer - Therapeutics Assessment

5. Anal Cancer - Companies Involved in Therapeutics Development

6. Anal Cancer - Drug Profiles

7. Anal Cancer - Dormant Projects

8. Anal Cancer - Discontinued Products

9. Anal Cancer - Product Development Milestones

10. Appendix

Companies Mentioned

  • Antiva Biosciences Inc.
  • Bayer AG
  • BeiGene Ltd.
  • Bristol-Myers Squibb Co.
  • Cleveland BioLabs Inc.
  • Cue Biopharma Inc.
  • CytomX Therapeutics Inc.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corp.
  • Genentech Inc.
  • IMV Inc.
  • Incyte Corp.
  • ISA Pharmaceuticals B.V.
  • Kite Pharma Inc.
  • MedImmune LLC
  • Merck & Co. Inc.
  • Merck KGaA
  • OncoMed Pharmaceuticals Inc.
  • Onconova Therapeutics Inc.
  • Ono Pharmaceutical Co. Ltd.
  • PDS Biotechnology Corp.
  • Sierra Oncology Inc.
  • THEVAX Genetics Vaccine USA Inc.
  • Transgene S.A.
  • Virion Therapeutics LLC

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ff85m8

View source version on businesswire.com:https://www.businesswire.com/news/home/20190416005549/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs ,Colon Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/16/2019 08:15 AM/DISC: 04/16/2019 08:15 AM